Copperhead Envenomation Observational Study

May 10, 2013 updated by: BTG International Inc.

Observational Study of Recovery From Copperhead Snake Envenomation

The primary objective of the study is to evaluate the responsiveness and utility of several clinical outcome assessments in the setting of copperhead snakebite. The secondary objective is to characterize the clinical course of signs, symptoms and impairment during the recovery phase of copperhead snakebite.

Study Overview

Status

Completed

Detailed Description

This observational study will document the patient's recovery from copperhead snakebite. All care provided will be at the discretion of the treating physician in accordance with the local standard of care.

Study Type

Observational

Enrollment (Actual)

20

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Kentucky
      • Lexington, Kentucky, United States, 40536
        • University of Kentucky Chandler Medical Center
    • Louisiana
      • Shreveport, Louisiana, United States, 71103
        • LSU Health Sciences Center
    • Michigan
      • Jackson, Michigan, United States, 39216
        • University of Mississippi Medical Center
    • Missouri
      • St. Louis, Missouri, United States, 76104
        • Washington University
    • North Carolina
      • Durham, North Carolina, United States, 27710
        • Duke Medical Center
      • Greenville, North Carolina, United States, 27834
        • Vidant Health
    • Texas
      • Bryan, Texas, United States, 77802
        • St. Joseph Regional Health Center
      • Ft. Worth, Texas, United States, 76104
        • Harris Methodist Hospital
      • Temple, Texas, United States, 76508
        • Scott and White Hospital
    • Virginia
      • Charlottesville, Virginia, United States, 22908
        • University of Virginia, Blue Ridge PC
      • Richmond, Virginia, United States, 23219
        • Virginia Commonwealth University Richmond

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Males and non-pregnant females at least 18 yrs of age with evidence of copperhead envenomation on an extremity distal to the knee or elbow that present for care at a health care facility within 24 hours of envenomation.

Description

Inclusion Criteria:

  • Envenomation by a copperhead snake
  • Presentation for care at a health care facility within 24 hrs of envenomation
  • Envenomation on an extremity distal to the knee or elbow
  • Clinical evidence of venom effect (limb swelling and/or tenderness)
  • Enrollment can be completed within 48 hrs of envenomation prior to discharge
  • Patient is willing and able to complete follow-up schedule of assessments
  • Patient is able to read, comprehend and sign IRB approved informed consent
  • Patient is able to read and comprehend written assessment tools
  • Patient is at least 18 yrs old
  • Patient is sober, competent and able to complete verbal and written informed consent

Exclusion Criteria:

  • Patient is pregnant or breastfeeding
  • Patient is a prisoner
  • Patient has distracting injury, condition with acute pain or functional impairment, and/or is unable to make a reliable self-report of status
  • Patient has had previous snake envenomation to any body area within 30 days prior to screening/enrollment, regardless of whether antivenom was administered
  • Patient had an acute traumatic or medical event, surgery, or exacerbation of pre-existing medical or surgical condition effecting the envenomated extremity within 30 days prior to screening/enrollment
  • Patient has participated in a clinical study involving and investigational pharmaceutical product or device within 3 months prior to screening that may have impact on clinical outcomes of snakebite
  • Patient has previously participated in this study
  • Patient is, in the investigator's opinion, otherwise unsuitable for participation. Note: Treatment with antivenom prior to eligibility evaluation is not an exclusion criterion

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Patient Global Assessment of Recovery (PGAR)
Time Frame: Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
Numeric Pain Rating Scale (NPRS)
Time Frame: Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
Numeric Swelling Score (NSS)
Time Frame: Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
SF36v2 (Acute Version)
Time Frame: Time of Discharge, Day 7, Day, 14, Day 21, and Day 28
Time of Discharge, Day 7, Day, 14, Day 21, and Day 28
Swelling Figure-of-8 Measurement
Time Frame: Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
Grip Strength
Time Frame: Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
Walking Speed
Time Frame: Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
Patient Global Impression of Change (PGIC)
Time Frame: Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
Return to Work/School/ADLs
Time Frame: Day 3, Day 7, Day 14, Day 21, and Day 28
Day 3, Day 7, Day 14, Day 21, and Day 28
Patient-Specific Functional Scale (PSFS)
Time Frame: Day 3, Day 7, Day 14, Day 21, and Day 28
Day 3, Day 7, Day 14, Day 21, and Day 28
WPAI:SHP V2
Time Frame: Day 3, Day 7, Day 14, Day 21, and Day 28
Day 3, Day 7, Day 14, Day 21, and Day 28
Disorders of the Arm, Shoulder, and Hand (DASH)
Time Frame: Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
Lower Extremity Functional Scale
Time Frame: Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28
Time of Discharge, Day 3, Day 7, Day 14, Day 21, and Day 28

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2012

Primary Completion (Actual)

November 1, 2012

Study Completion (Actual)

April 1, 2013

Study Registration Dates

First Submitted

July 25, 2012

First Submitted That Met QC Criteria

July 26, 2012

First Posted (Estimate)

July 27, 2012

Study Record Updates

Last Update Posted (Estimate)

May 13, 2013

Last Update Submitted That Met QC Criteria

May 10, 2013

Last Verified

September 1, 2012

More Information

Terms related to this study

Other Study ID Numbers

  • BTG-PR005-001

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Copperhead Snake Envenomation

3
Subscribe